DavidMorganMD

PubMed

• 8 citations
  The iRregimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.
  Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, Jia Ruan, Kirit M Ardeshna, Roderick Johnson, Gregor Verhoef, David Cunningham, Sven de Vos, Shireen Kassam, ...> ;Eclinicalmedicine. 2023 Feb 1
• 72 citations
  Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multic...
  Catherine Diefenbach, Fangxin Hong, Richard F. Ambinder, Jonathon B. Cohen, Michael J. Robertson, Kevin A. David, Ranjana H. Advani, Timothy S. Fenske, Stefan K. Barta...> ;The Lancet. Haematology. 2020 Sep 1
• 88 citations
  Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL
  Andre Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, Javier Munoz, David S. Morgan, Nam H. Dang, Mark Knapp, Maria Delioukina, Edwin C. Kingsley, Jerry Ping, Darrin M...> ;Blood. 2019 Sep 26
• 12 citations
  Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma
  Tarsheen K. Sethi, Alexandra E. Kovach, Natalie S Grover, Li-Ching Huang, Laura A. Lee, Samuel M. Rubinstein, Yang Wang, David S. Morgan, John P. Greer, Steven I. Park...> ;Leukemia & Lymphoma. 2019 Jun 11
• 7 citations
  Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of PET scan in treatment ...
  Van T Nguyen, Priyanka A. Pophali, Judy P. Tsai, Deepa Jagadeesh, Robert M. Dean, Brad Pohlman, David S. Morgan, John P. Greer, Mitchell R. Smith, Brian T. Hill, Nishi...> ;British Journal of Haematology. 2017 Nov 1
• 12 citations
  Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma.
  Tarsheen K. Sethi, Van T Nguyen, Shaoying Li, David S. Morgan, John P. Greer, Nishitha Reddy> ;Therapeutic Advances in Hematology. 2017 Jan 1
• Association of 4p14 TLR locus with antibodies to Helicobacter pylori.
  Sung, H.,Camargo, M. C.,Yu, K.,Weinstein, S. J.,Morgan, D. R.,Albanes, D.,Rabkin, C. S.> ;Genes Immun.. 2015 Aug 28
• Increased Helicobacter pylori-associated gastric cancer risk in the Andean region of Colombia is mediated by spermine oxidase.
  Chaturvedi, R.,de Sablet, T.,Asim, M.,Piazuelo, M. B.,Barry, D. P.,Verriere, T. G.,Sierra, J. C.,Hardbower, D. M.,Delgado, A. G.,Schneider, B. G.,Israel, D. A.,Romero-...> ;Oncogene. 2014 Sep 02
• 32 citations
  A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma
  Victor Yazbeck, Danielle Shafer, Edward B. Perkins, Domenico Coppola, Lubomir Sokol, Kristy L. Richards, Thomas B. Shea, Jia Ruan, Samir Parekh, Roger Strair, Christop...> ;Clinical Lymphoma, Myeloma & Leukemia. 2011 Nov 18
• Join now to see all

Abstracts/Posters

• Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation Cohort
  David Morgan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell_like (Non-GCB) Diffus...
  David Morgan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019